PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2011; 32(01): 12-16
DOI: 10.4103/0971-5851.81884
REVIEW ARTICLE

Gastric cancer in India

Atul Sharma
Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Venkatraman Radhakrishnan
Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
› Institutsangaben Source of Support Nil.
› Weitere Informationen
  als PDF herunterladen Lizenzen und Reprints

Abstract

The incidence of gastric cancer in India is low compared to developed countries, though there are certain geographical areas (Southern part and northeastern states of country) where the incidence is comparable to high-incidence areas of world. Despite the large number of patients being treated for gastric cancer, there are not sufficient publications discussing associated risk factors and outcomes in these patients. This article discusses relevant Indian epidemiological and clinical studies about gastric cancers. This article also highlights the gap in publication from India and developed countries regarding gastric cancer and stresses on collaborative efforts of the Indian scientific community to conduct epidemiological, pathological, and clinical studies to have a new standard of care for Indian patients.

Keywords

Clinical - epidemiological studies - gastric cancer - India


Publikationsverlauf

Artikel online veröffentlicht:
16. August 2021

© 2011. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 V Rao DN, Ganesh B. Estimate of cancer incidence in India in 1991. Indian J Cancer 1998;35:10-8.
  • 2 Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: Epidemiology, pathology and treatment. Ann Oncol 2003;14:ii31-6.
  • 3 Pavithran K, Doval DC, Pandey KK. Gastric cancer in India. Gastric Cancer 2002;5:240-3.
  • 4 Yeole BB. Trends in cancer incidence in esophagus, stomach, colon, rectum and liver in males in India. Asian Pac J Cancer Prev 2008;9:97-100.
  • 5 Satyanarayana L, Asthana S. Life time risk for development of ten major cancers in India and its trends over the years 1982 to 2000. Indian J Med Sci 2008;62:35-44.
  • 6 Rastogi T, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R, et al. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol 2008;37:147-60.
  • 7 Malhotra SL. Geographical distribution of gastrointestinal cancers in India with special reference to causation. Gut 1967;8:361-72.
  • 8 Mathew A, Gangadharan P, Varghese C, Nair MK. Diet and stomach cancer: A case-control study in South India. Eur J Cancer Prev 2000;9:89-97.
  • 9 Ponnala D, Madireddi S. Evaluation of risk factors for gastric cancer. Int J Appl Biol Pharm Technol 2010;1:158-61.
  • 10 Indian Council of Medical Research (ICMR), First Report of the Population Based Cancer Registries Under North Eastern Regional Cancer Registry 2003-2004. Available from: http://www.icmr.nic.in/ncrp/first_report_2003-04/first_report.htm [last cited on 2010 Sep 6].
  • 11 Phukan RK, Zomawia E, Hazarika NC, Baruah D, Mahanta J. High prevalence of stomach cancer among the people of Mizoram, India. Curr Sci 2004;87:285-6.
  • 12 Phukan RK, Zomawia E, Narain K, Hazarika NC, Mahanta J. Tobacco use and stomach cancer in Mizoram, India. Cancer Epidemiol Biomarkers Prev 2005;14:1892-6.
  • 13 Sumathi B, Ramalingam S, Navaneethan U, Jayanthi V. Risk factors for gastric cancer in South India. Singapore Med J 2009;50:147-51.
  • 14 Malik GM, Mubarik M, Kadla SA, Durrani HA. Gastric cancer profile in Kashmiri population with special dietary habits. Diagn Ther Endosc 2000;6:83-6.
  • 15 Rocco A, Nardone G. Diet, H pylori infection and gastric cancer: Evidence and controversies. World J Gastroenterol 2007;13:2901-12.
  • 16 Singh K, Ghoshal UC. Causal role of Helicobacter pylori infection in gastric cancer: An Asian enigma. World J Gastroenterol 2006;12:1346-51.
  • 17 D′souza MA, Singh K, Shrikhande SV. Surgery for gastric cancer: An evidence-based perspective. J Cancer Res Ther 2009;5:225-31.
  • 18 Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-62.
  • 19 Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: Morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767-73.
  • 20 Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522-30.
  • 21 Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069-77.
  • 22 Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004;30:303-8.
  • 23 Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D′Amico TA, Das P, et al. Gastric cancer. J Natl Compr Canc Netw 2010;8:378-409.
  • 24 Shrikhande SV, Shukla PJ, Qureshi S, Siddachari R, Upasani V, Ramadwar M, et al. D2 lymphadenectomy for gastric cancer in Tata Memorial Hospital: Indian data can now be incorporated in future international trials. Dig Surg 2006;23:192-7.
  • 25 Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
  • 26 Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20.
  • 27 Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10:49-58.
  • 28 Sharma A, Raina V, Lokeshwar N, Deo SV, Shukla NK, Mohanti BK. Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction. Indian J Cancer 2006;43:16-9.
  • 29 Shukla NK, Deo SV, Asthana S, Raina V, Dronamaraju SS. Neoadjuvant chemotherapy in advanced gastric cancer-results of a pilot study. Trop Gastroenterol 2002;23:94-6.
  • 30 Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-6.
  • 31 Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PW, Ajani JA, et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 2001;8:519-24.
  • 32 Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
  • 33 Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial. Lancet 2010;376:687-97.